Skip to Content

Deep PSA declines with apalutamide is associated with lower risk for worsened QoL

An additional study to the TITAN and SPARTAN Studies supports findings suggesting preserved quality of life despite changes in prostate-specific antigen in patients treated with apalutamide.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top